Actively Recruiting
Randomized Study of ITI-1284 Tablets Versus Placebo for Treating Generalized Anxiety Disorder in Patients with Inadequate Prior Treatment Response
Led by Intra-Cellular Therapies, Inc. · Updated on 2026-11-03
570
Participants Needed
51
Research Sites
40 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug ITI-1284 as a monotherapy treatment in patients diagnosed with moderate to severe Generalized Anxiety Disorder GAD who have not responded adequately to previous GAD treatments. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to assess the efficacy, safety, and tolerability of ITI-1284 in this patient population. Participants are randomly assigned to one of three groups ITI-1284 10 mg tablet, ITI-1284 20 mg tablet, or a matching placebo, all taken once daily by sublingual administration. The study compares these doses to placebo over a treatment period, with assessments planned at Week 6. During the study, participants will be monitored for changes in anxiety using the Hamilton Anxiety Rating Scale HAM-A and the Clinical Global Impression Scale-Severity CGI-S at Week 6. Safety and tolerability will also be evaluated. The total duration includes the screening, treatment, and follow-up periods leading up to the primary completion date in October 2027 and study completion in July 2028.
CONDITIONS
Brief Title
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here